Poland· PL-100392362
Vosevi
A sofosbuvir, velpatasvir and voxilaprevir product containing sofosbuvirum + velpatasvirum + voxilaprevirum, registered in Poland by Gilead Sciences Ireland UC. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- IT Italy$1097.10
- CH Switzerland$447.39
The record
At a glance
URPL (Poland)- Active substance
- Sofosbuvirum + Velpatasvirum + Voxilaprevirum
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Poland (PL)
- ATC code
- J05AP56
- ATC class
- Sofosbuvir, velpatasvir and voxilaprevir
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05391507143303
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sofosbuvir, velpatasvir and voxilaprevir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVOSEVIGilead Sciences Ireland UC, Carrigtohill
- United StatesVoseviGilead Sciences, Inc.
- IcelandVoseviGilead Sciences Ireland UC*
- NetherlandsVosevi 200 mg/50 mg/50 mg, filmomhulde tablettenGilead Sciences Ireland UC
- FinlandVoseviGilead Sciences Ireland UC
- SwedenVosevi 200 mg/50 mg/50 mg Filmdragerad tablettGilead Sciences Ireland UC
- IrelandVosevi 200 mg/50 mg/50 mg film-coated tabletsGilead Sciences Ireland UC
- CanadaVOSEVIGILEAD SCIENCES CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vosevi
- Liechtenstein · Vosevi
- Norway · Vosevi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6b66adb7-29e8-402d-84ce-bed3b07d5566 GET /v1/drugs/6b66adb7-29e8-402d-84ce-bed3b07d5566?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "400 mg + 100 mg + 100 mg",
"packaging": "05391507143303 ¦ Rpz ¦ EU/1/17/1223/001 ¦ 123943\n28 tabl.",
"substance": "Sofosbuvirum 400 mg + Velpatasvirum 100 mg + Voxilaprevirum 100 mg",
"common_name": "Sofosbuvirum + Velpatasvirum + Voxilaprevirum",
"pl_product_id": "100392362",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about sofosbuvir, velpatasvir and voxilaprevir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.